Countervailing influence of tumor necrosis factor-α and nitric oxide in endotoxemia

Journal of the American Society of Nephrology

Volumn 12, Issue 6, 2001, Pages 1204-1210

  Jaimes, Edgar A ^a,b   Del Castillo, Domingo ^a   Rutherford, Mark S ^a   Raij, Leopoldo ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTOXEMIA; GLOMERULUS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; THROMBOGENICITY; THROMBOSIS;

EID: 0035019369     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bone R: The pathogenesis of sepsis. Ann Intern Med 115: 457-469, 1991
2. Dinarello C: Interleukin-1 and interleukin-1 antagonism. Blood 8: 1627-1652, 1991
3. Parrillo J: Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477, 1993
4. Del Castillo D, Agarwal A, Jaimes E, Raij L: Glomerular and vascular tissues do not down-regulate nitric oxide synthesis during protracted endotoxemia. Kidney Int 52: 460-467, 1997
5. Lamas S, Michel T, Brenner B, Marsden P: Nitric oxide synthesis in endothelial cells: Evidence for a pathway inducible by TNF-α. Am J Physiol 261: C634-C641, 1991
6. Lamas S, Michel T, Collins T: Effects of interferon-γ on nitric oxide synthase activity and endothelin production by vascular endothelial cells. J Clin Invest 90: 879-887, 1992
7. Busse R, Mulsch A: Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 275: 87-90, 1990
8. Jaimes E, Nath K, Raij L: Hydrogen peroxide down-regulates IL-1 driven mesangial iNOS activity: Implications for glomerulonephritis. Am J Physiol 272: F721-F728, 1997
9. Shultz P, Tayeh M, Marletta M, Raij L: Synthesis and action of nitric oxide in rat glomerular mesangial cells. Am J Physiol 261: F600-F606, 1991
10. Zembowicz A, Vane J: Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage cell line. Proc Natl Acad Sci USA 89: 2051-2055, 1992
11. Moncada S, Palmer M, Higgs E: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109-142, 1991
12. Radomski M, Palmer R, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87: 5193-5197, 1990
13. G-Methyl-L-arginine inhibits tumor necrosis factor-1 induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87: 3629-3632, 1990
14. Shultz P, Raij L: Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 90: 1718-1725, 1992
15. Westberg G, Shultz P, Raij L: Exogenous nitric oxide prevents endotoxin-induced glomerular thrombosis in rats. Kidney Int 46: 711-716, 1994
16. Schwartz D, Mendonca M, Schwartz I, Xia Y, Satriano J, Wilson C, Blantz R: Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 100: 439-448, 1997
17. Tracey K, Beutler B, Lowry S: Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-474, 1986
18. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871, 1985
19. Lewis M, Tartaglia L, Lee A, Bennett G, Rice G, Wong G, Chen E, Goeddel D: Cloning and expression of cDNA for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 88: 2830-2834, 1991
20. Shalaby M, Sundan A, Loetscher H, Brockhaus M, Lesslauer W, Espevik T: Binding and regulation of cellular functions by monoclonal antibodies against tumor necrosis receptors. J Exp Med 172: 1517-1520, 1990
21. Zheng L, Fisher G, Miller R, Peschon J, Lynch D, Lenardo M: Induction of apoptosis in mature T cells by tumor necrosis factor. Nature 377: 348-351, 1995
22. Tartaglia L, Goeddel D, Reynolds C, Figari I, Weber R, Fendly B, Palladino M: Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol 151: 4637-4641, 1993
23. Erickson S, de Sauvage F, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan K, Schreiber R, Goeddel D, Moore M: Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372: 560, 1994
24. Lucas R, Juillard P, Decoster E, Redard M, Burger D, Donati Y, Giroud C, Monso-Hinard C, De Kesel T, Buurman WA, Moore MW, Dayer JM, Fiers W, Bluethmann H, Grau GE: Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol 27: 1719-1725, 1997
25. Archipoff G, Beretz A, Freyssinet JM, Klein-Soyer C, Brisson C, Cazenave JP: Heterogeneous regulation of constitutive thrombo-modulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem J 273: 679-684, 1991
26. Scarpati EM, Sadler JE: Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 264: 20705-20713, 1989
27. Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR: Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogeneous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest 93: 2073-2083, 1994
28. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM: TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160: 943-952, 1998
29. Amirkhosravi A, Meyer T, Warnes G, Amaya M, Malik Z, Biggerstaff JP, Siddiqui FA, Sherman P, Francis JL: Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor. Thromb Haemost 80: 598-602, 1998
30. Kollias G, Douni E, Kassiotis G, Kontoyiannis D: On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 169: 175-194, 1999
31. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17: 975-978, 1989
32. Ding A, Nathan C, Stuehr D: Release of reactive nitrogen intermediates and reactive oxygen species from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412, 1988
33. MacNaul KL, Hutchinson NI: Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun 196: 1330-1334, 1993
34. Prodjosudjadi W, Gerritsma J, Klar-Mohamad N, Gerritsen A, Brujin J, Daha M, van Es L: Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by proximal tubular epithelial cells. Kidney Int 48: 1477, 1995
35. Ishikura H, Takahashi C, Kangawa K, Hirata H, Imai K, Yoshiki T: Cytokine regulation of ICAM-1 expression on human renal tubular epithelial cells in vitro. Transplantation 51: 1272-1275, 1991
36. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, Lobb R: Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59: 1203-1211, 1989
37. Denton MD, Marsden PA, Luscinskas FW, Brenner BM, Brady HR: Cytokine-induced phagocyte adhesion to human mesangial cells: Role of CD11/CD18 integrins and ICAM-1. Am J Physiol 261: F1071-F1079, 1991
38. Schmid E, Muller TH, Budzinski RM, Pfizenmaier K, Binder K: Lymphocyte adhesion to human endothelial cells induces tissue factor expression via a juxtacrine pathway. Thromb Haemost 73: 421-428, 1995
39. Agnoletti L, Curello S, Bachetti T, Malacarne F, Gaia G, Comini L, Volterrani M, Bonetti P, Parrinello G, Cadei M, Grigolato PG, Ferrari R: Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: Role of tumor necrosis factor-alpha. Circulation 100: 1983-1991, 1999
40. Yoshizumi M, Parella M, Burnett J, Lee M: Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half life. Circ Res 73: 205-209, 1993
41. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24: 1431-1440, 1996
42. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277: 1531-1538, 1997
43. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697-1702, 1996
44. Pellegrini J, Puyana J, Lapchak P, Kodys K, Millergraziano C: A membrane TNF-alpha/TNFR ratio correlates to MODS score and mortality. Shock 6: 389-396, 1996
45. Hesse D, Tracey K, Fong Y, Manogue K, Palladino MJ, Cerami A: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 166: 147-153, 1988
46. Deckert-Schluter M, Bluethmann H, Rang A, Hof H, Schluter D: Crucial role of TNF receptor type 1 (p55), but not of TNF receptor type 2 (p75), in murine toxoplasmosis. J Immunol 160: 3427-3436, 1998
47. Salkowski CA, Detore G, McNally R, van Rooijen N, Vogel SN: Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo: The roles of macrophages, endogenous IFN-gamma, and TNF receptor-1-mediated signaling. J Immunol 158: 905-912, 1997
48. Yap GS, Scharton-Kersten T, Charcst H, Sher A: Decreased resistance of TNF receptor p55-and p75-deficient mice to chronic toxoplasmosis despite normal activation of inducible nitric oxide synthase in vivo. J Immunol 160: 1340-1345, 1998
49. Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 90: 693-698, 1992
50. Noiri E, Kuwata S, Nosaka K, Tokunaga K, Juji T, Shibata Y, Kurokawa K: Tumor necrosis factor-alpha mRNA expression in lipopolysaccharide-stimulated rat kidney. Chronological analysis of localization. Am J Pathol 144: 1159-1166, 1994